A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

NCT06119581 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1264

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis

Interventions

DRUG: LY3537982
DRUG: Pembrolizumab
DRUG: Placebo
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Pemetrexed

Sponsor

Eli Lilly and Company